Rockwell Medical Inc (RMTI)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$7.60-5.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · RMTI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -65.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 10.9% |
Growth built into the price is above our model estimate.
The price assumes 76.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 12 industry peers
RMTI — credit agreement
Dated 2026-11-03
Entry into a Material Definitive Agreement. Equity and Asset Purchase Agreement On November 2, 2026, Rockwell Medical, Inc. (the “Company”) entered into an Equity and Asset Purchase Agreement (the “Purchase Agreement”) with Vantive Limited, a company incorporated under the laws of Jersey (“Vantive”). Pursuant to the Purchase Agreement, the Company agreed to acquire Vantive’s in-center hemodialysis business in 35 jurisdictions, including the United States, consisting of the development, manufa…
Why it matters: Adjusted EBITDA was still negative $0.4M for the first half. Positive Q3 results would support the $1M to $2M full-year goal.
Supportive ifQ3 adjusted EBITDA is above $0, and the company keeps its $1M to $2M full-year goal.
Worry ifQ3 adjusted EBITDA remains at or below $0, or management cuts the $1M to $2M goal.
Why it matters: Q2 margin reached 18%, up from 16% a year earlier. Holding that level would support the 2026 margin goal.
Supportive ifQ3 gross margin is at least 18%, with the full-year outlook still at 18% to 22%.
Worry ifQ3 gross margin falls below 18%, or management lowers the 18% to 22% full-year range.
Why it matters: New and renewed product deals could add sales, but Q1 sales fell after one customer bought less. Q3 results can show whether new demand offsets that drop.
Watch forQ3 sales rise from a year ago. The company links growth to orders from Heritage Dialysis or aQua Dialysis.
Also watch forQ3 sales fall year over year, or the company reports lower orders from a key customer.
Why it matters: Q2 sales grew 11% year over year, but first-half sales were nearly flat. Q3 results will test the $70M to $75M full-year sales range.
Watch forOn November 12, Q3 sales are at least $17.6M, keeping full-year sales on pace for the $70M to $75M range.
Also watch forQ3 sales are below $17.6M, or management cuts its $70M to $75M sales range.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $680 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,881 loss on $10,000 · 58.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.